MERTK, MER proto-oncogene, tyrosine kinase, 10461

N. diseases: 154; N. variants: 31
Disease: Primary malignant neoplasm ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.090 Biomarker group BEFREE This work provides a mechanism underlying MERTK-mediated Akt activation and survival signaling in kidney cancer. 30944303 2019
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.090 Biomarker group BEFREE Oncogenic dependency on members of the TAM tyrosine kinase receptor family (TYRO3, AXL, MERTK) has been reported in several cancer types, but their role in bladder cancer has never been explored. 30765874 2019
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.090 Biomarker group BEFREE TAM family members (TYRO3, AXL and MERTK) play essential roles in the resolution of inflammation and in infectious diseases and cancer. 31075180 2019
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.090 Biomarker group BEFREE This review will focus on PtdSer as a cofactor required for stimulating TYRO3, AXL and MERTK - comprising the TAM family of receptor tyrosine kinases by their ligands Protein S (PROS1) and growth-arrest-specific 6 (GAS6) in inflammation and cancer. 31775787 2019
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.090 Biomarker group BEFREE AXL is a member of the TYRO3-AXL-MER family of receptor tyrosine kinases, and has been revealed to be an important mediator of epithelial-mesenchymal transition (EMT) in several types of cancer. 29434888 2018
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.090 Biomarker group BEFREE MER proto-oncogene tyrosine kinase (MERTK) is a receptor tyrosine kinase that affects cancer cell proliferation. 29277773 2018
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.090 Biomarker group BEFREE The optimal design of treatment strategies to maximize the clinical benefit of these AXL and MER targeting agents are discussed in relation to the different cancer types and the types of resistance encountered. 28251492 2017
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.090 AlteredExpression group BEFREE In addition, UNC2025 increased sensitivity to methotrexate <i>in vivo</i>, suggesting that addition of MERTK-targeted therapy to current cytotoxic regimens may be particularly effective and/or allow for chemotherapy dose reduction.<b>Conclusions:</b> The broad-spectrum activity mediated by UNC2025 in leukemia patient samples and xenograft models, alone or in combination with cytotoxic chemotherapy, supports continued development of MERTK inhibitors for treatment of leukemia.<i>Clin Cancer Res; 23(6); 1481-92.©2016 AACR</i>. 27649555 2017
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.090 AlteredExpression group BEFREE On the one hand, knock-out of MERTK results in age-dependent autoimmunity characterized by failure of apoptotic cell clearance, while on the other, MERTK overexpression in cancer drives classical oncogene pathways leading to cell transformation. 25074939 2014